Edelman hires Yvette Venable and Jenny Heffron to grow healthcare team

Edelman has strengthened its management team with the appointment of two senior pharma communicators.

Jenny Heffron: bolsters Edelman's healthcare team
Jenny Heffron: bolsters Edelman's healthcare team

Yvette Venable and Jenny Heffron have both joined the agency's healthcare team as directors.

Venable was previously a senior comms strategist at drug firm Bristol-Myers Squibb EMEA, based in Paris, where she worked for more than three years. She was also European advoc­acy lead for the firm's ­oncology and diabetes portfolios.

At BMS, Venable focused on helping influence the environment for market access and new product launches. She had also previously held senior positions at Fleishman-Hillard and Ogilvy in the US.

Venable's key specialist ­areas are oncology, diabetes, healthcare diagnostics and market access.

Heffron has been working in the pharma industry for more than 17 years. She most recently worked at healthcare agency Synergy for five years. Before that, she worked in-house at Eli Lilly UK, Novartis UK and GlaxoSmithKline.

During her career, she has been responsible for directing UK, international and corporate comms programmes.

Heffron's specialist areas are mental health, osteoporosis and ophthalmology.

Edelman healthcare MD Steve Spurr said: ‘Between Yvette and Jenny, they bring a wealth of international and UK experience that will deepen Edelman's client counsel and programming.
‘With these appointments, we are now a 65-strong health team with domestic and international capabilities spanning medical education, market ­access, pharmaceutical and consumer health PR.'

Heffron's appointment is to a new role and she will focus on the UK market.

Venable has been brought in instead of getting maternity cover for a dir­ector andassociate director. Both will report to Spurr and are charged with helping to grow the healthcare practice.

Edelman was second in the latest PRWeek Healthcare league table (PRWeek, 26 June). Spurr said the agency's growth was partly fuelled by business wins with pharma firms Wyeth and Novo Nordisk.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in